roots-of-innovation-us-chamber-cover-image

Welcome to the fifth edition of the U.S. Chamber International IP Index, “The Roots of Innovation.” This year’s index recognizes the indispensable role of intellectual property (IP), in facilitating innovative and creative activity on a socially transformative scale.

Each economy in the Index presents a unique IP profile. As this Index has grown from 11 economies in its first edition to 45 in the current publication, it has become exceedingly clear that just as elections matter, so do IP policy choices. These choices are not simply a matter of East versus West, developed versus less-developed, or rich versus poor. Rather, the Index represents a broad spectrum of sovereign policy choices. Those choices have important consequences for each economy’s innovative and creative success, and for the collective welfare of all the world’s citizens.

big-idea-connectpreneur-logo

The Big Idea CONNECTpreneur Forum is a Community of over 5000 CEOs, Entrepreneurs, VCs and angels, CXOs and other business leaders in the Mid-Atlantic Region.

Each quarterly CONNECTpreneur Forum mashes up 400+ top founders, investors and business leaders for a morning breakfast event featuring awesome networking, newsmaking speakers, and a showcase of 7-8 exciting early stage companies.

This UNIQUE EVENT is like NONE OTHER in our region, due to the high quality of our attendees and participants, as well as our programming and unprecedented networking.

Most of the attendees are INVITATION ONLY, and we strictly limit service provider participation in order to maximize the experience for our Attendees and Sponsors.

illumina-logo

Illumina Accelerator, the genomics-based company creation engine focused on building early stage genomics startups welcomes three new companies to its fifth funding cycle. Since its inception in 2014, Illumina Accelerator has helped startups validate and create next-generation sequencing applications and bring those solutions to market. To date, Illumina Accelerator has invested in 13 startups working to advance breakthrough applications in genomics.

Join us as we showcase accomplishments and discuss opportunities for the future of the BioHealth industry in the BioHealth Capital Region.

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Paragon Bioservices, INOVA, University System of Maryland and MedImmune/AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum — a catalyst for public-private, academia-industry, and seasoned-rising stars to join forces for the good of the region. We are excited to bring you an exceptional line up of speakers. The program will feature sessions that focus on Advancing Science and Accelerating Innovation.

April 19 – 20, 2017

One MedImmune Way, Gaithersburg, MD 20878

Register at www.bhcrforum.com

For more information, contact Amy Rubenstein at 513-238-8606 or This email address is being protected from spambots. You need JavaScript enabled to view it..

red-flag-pixa

After listening to hundreds of startup pitches, and reading even more business plans, most new venture investors develop their own favorite list of “red flags” that signal the beginning of the end of their interest. Others, like Guy Kawasaki, have irreverently called some of these “entrepreneur lies,” but I prefer to think of them as innocent enhancements or omissions that can kill your deal.

At any rate, here is my own list of red flags, from my years of experience advising and investing in aspiring entrepreneurs, which cause me to lose interest and start looking for a way out the door:

cambridge-university-press-logo

In order to address the unmet needs and create opportunities that benefit patients with rare disease in India, a group of volunteers created a not-for-profit organization named Organization for Rare Diseases India (ORDI; www.ordindia.org). ORDI plans to represent the collective voice and advocate the needs of patients with rare diseases and other stakeholders in India. The ORDI team members come from diverse backgrounds such as genetics, molecular diagnostics, drug development, bioinformatics, communications, information technology, patient advocacy and public service. ORDI builds on the lessons learned from numerous similar organizations in the USA, European Union and disease-specific rare disease foundations in India. In this review, we provide a background on the landscape of rare diseases and the organizations that are active in this area globally and in India. We discuss the unique challenges in tackling rare diseases in India, and highlight the unmet needs of the key stakeholders of rare diseases. Finally, we define the vision, mission, goals and objectives of ORDI, identify the key developments in the health care context in India and welcome community feedback and comments on our approach.

tesla-logo

Tesla and SpaceX founder Elon Musk has a suggestion for humans who want to stay relevant in a future of artificial intelligence: merge with the machines.

"Over time I think we will probably see a closer merger of biological intelligence and digital intelligence," Musk said at the World Government Summit in Dubai, according to CNBC. "It's mostly about bandwidth, the speed of the connection between your brain and the digital version of yourself, particularly output."

bbc-entrepreneurial-training-and-consulting-logo

Last month, we outlined our top 10 do's and don'ts for getting your Phase I NIH proposal in shape and ready to submit before the April 5 deadline. This month we continue that theme by presenting what we have determined, over years of reviewing proposals, to be our top 10 brilliant ideas or stupid mistakes for Phase II proposals. Here are our favorites:

orgenesis-logo

Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian subsidiary, Orgenesis SPRL, has received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budget of EUR 12.3 million ($12.8 million) support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The project support will be for a period of three years commencing on January 1, 2017.

Of the approved amount, a total of EUR 3.3 million is budgeted for a development work at our Belgian-based subsidiary, MaSTherCell S.A.

mri-brain-pixa

In labs testing how brain implants could help people with physical disabilities, tales of success can be bittersweet.

Experiments like those that let a paralyzed person swig coffee using a robotic arm, or that let blind people “see” spots of light, have proven the huge potential of computers that interface with the brain. But the implanted electrodes used in such trials eventually become useless, as scar tissue forms that degrades their electrical connection to brain cells (see “The Thought Experiment”).

brian-darmody-2-umd-image

Which state has the nation’s most research-intensive economy? California? Massachusetts? North Carolina?

Actually it’s Maryland. A greater portion of Maryland’s economy comes from private, federal, and university research spending than any state (with the exception of rural New Mexico with its two large federal labs).  But not enough of us recognize that.

nhlbi-nih-logo

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices:

  • Impact of Washington, DC Area Federal Office Operating Status on NIH Grant Application Due Dates 
  • Notice of NIA's Participation in PA-17-101 "Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations - An ORWH FY17 Administrative Supplement (Admin Supp)"
  • NHLBI Priorities for HIV Research and Funding 
  • Notice of NLM's Participation in PA-17-101 "Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations An ORWH FY17 Administrative Supplement (Admin Supp)"
emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to develop monoclonal antibody therapeutics for viral hemorrhagic fever. This task order will utilize the company’s Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland. Using monoclonal antibodies from Mapp Biopharmaceutical Inc., the company will conduct technology transfer of process materials and information, perform process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance. The task order consists of a 36-month period of performance with a base task order valued at $7.4 million and options that, if executed, will bring the total task order value over three years to up to $30.5 million.

national-mall-dc-pixa

Scientists are no strangers to having their work questioned by lawmakers, and now they are fighting back.

On April 22, scientists and their supporters will hold a March for Science to advocate for science and evidence-based research in policies. The main march will be held in Washington, D.C., and satellite marches will be held in other cities, as they were with the Women’s March the day after the inauguration. And the march’s organizers say they aren’t just fighting for more funding for science, or more influence in policy, but also to raise awareness about the type of research they’re doing.

white-house-washingington-dc-pixa

The recent flurry of activity around the Affordable Care Act (ACA) has many people confused about where it stands, and what the employer's obligations are. The following summarizes the activity so far.

Legislative Repeal Activity

A popular meme suggests that the Senate voted to eliminate virtually all of the provisions of the ACA, including the ability to obtain insurance in spite of pre-existing conditions, the requirement to cover adult children up to the age of 26, etc. This is not the case.

us-hhs-gov-logo

President Donald Trump’s new health secretary took office Friday after becoming the latest Cabinet nominee to eke out a confirmation victory in the bitterly divided Senate.

Vice President Mike Pence administered the oath of office to Tom Price, of Georgia, at the White House hours after the Senate confirmed him 52-47 in a party-line vote. That roll call came in the dead of night, thanks to Democrats’ tactic of forcing prolonged debates to broadcast their opposition to Trump and his team.

umd-maryland-logo

Researchers from the University of Maryland College Park (UMD) and Baltimore (UMB) campuses have developed a blood test that could help doctors more quickly diagnose schizophrenia and other disorders. Their study, "Redox Probing for Chemical Information of Oxidative Stress," was recently published in the journal Analytical Chemistry.

"We hope our new technique will allow a more rapid detection and intervention for schizophrenia, and ultimately lead to better outcomes," said Gregory Payne, one of the authors and a joint professor with UMD's Fischell Department of Bioengineering (BIOE) and the Institute for Bioscience and Biotechnology Research (IBBR).

surgigyn-logo

Gynecological surgery device developer SurgiGyn said today it inked an exclusive license arrangement with the University of Maryland, Baltimore for laparoscopic surgical device technology developed at the University.

The Baltimore, Md.-based company said it also closed a seed round of funding from UM Ventures and a private investor, with funds slated to support accelerated development of its uterine electrosurgical device

bio-new-logo

The Biotechnology Innovation Organization (BIO) issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

"We look forward to working with President Trump and his team to enact policies that ensure better access to and affordability of today’s medicines and the vision the President laid out in his inaugural address ‘….to free the earth from the miseries of disease, and to harness the energies, industries and technologies of tomorrow.’ The ideas the President laid out in his meeting today--policies that would cut unnecessary regulation, enforce fair trade, increase competition, support small companies' ability to attract capital and strengthen and promote market-based solutions--are ideas that BIO has been advocating for and working to build consensus on with others in the healthcare system.  They will go a long way toward ensuring that patients have affordable access to today's innovative medicines and that our companies have the policy and regulatory environment they need to bring a new generation of breakthrough medicines to our children and grandchildren.

women-in-bio-logo

Thursday, February 23, 2017 6:00 p.m. – 8:00 p.m. EST

Johns Hopkins University – Montgomery Campus 106-110 A&R Building 9601 Medical Center Drive Rockville, MD 20850

Washington DC/Baltimore Chapter of Women In Bio is presenting a program to learn about how bioscience discoveries move from the bench to the market. The route from discovery to market is not linear. Our panelists will relay their experiences with clinical trials, manufacturing, and marketing and will discuss how each of these aspects interacts along the way. Whether you are looking to enter the world of bench to market or are just curious about the process, this will be an informative and fun event. Moderated by Lynn Johnson Langer, Program Director, Sr. Lecturer, Johns Hopkins University, our panel includes the following individuals:

  • Neta Nelson - Associate Director, Clinical Operations & Project Management, Technical Resources International, Inc.
  • Maura Kahn - Vice President, Business Development and Marketing, Noxilizer, Inc.
  • Kathy Webb - Senior Director GMP Operations, Paragon Bioservices, Inc.

robert-l-caret-usm-image

On the first two days of February, I testified before Maryland legislative committees in support of Governor Larry Hogan's FY 2018 budget proposal for the University System of Maryland (USM).

Governor Hogan has proposed state support for USM of $1.35 billion. This is an increase of $26.6 million --- or approximately 2 percent --- over the final FY 2017 budget, which includes the November Board of Public Works reduction of $14.2 million.

biobuzz-networking-event-logo

Thursday February 16, 2017 from 5:00 PM to 7:00 PM EST 

Join BioBuzz and founding sponsor The Johns Hopkins University Montgomery County Campus at Growlers in Gaithersburg on February 16th for our 1st networking event of 2017. The Johns Hopkins University Montgomery County Campus offers part-time graduate courses in several disciplines, including education, biotechnology and liberal arts. Students attend classes in the evenings and on Saturdays, enabling them to hold full-time jobs during the day. Depending on the degree area, students can fully complete their coursework in Montgomery County. Other students take some courses in Baltimore and/ or online.

stem-cells-pixa

Understanding how mechanics complement bio-signaling in defining patterns during morphogenesis is an outstanding challenge. Here, we utilize the multicellular polyp Hydra to investigate the role of the actomyosin cytoskeleton in morphogenesis. We find that the supra-cellular actin fiber organization is inherited from the parent Hydra and determines the body axis in regenerating tissue segments. This form of structural inheritance is non-trivial because of the tissue folding and dynamic actin reorganization involved. We further show that the emergence of multiple body axes can be traced to discrepancies in actin fiber alignment at early stages of the regeneration process. Mechanical constraints induced by anchoring regenerating Hydra on stiff wires suppressed the emergence of multiple body axes, highlighting the importance of mechanical feedbacks in defining and stabilizing the body axis. Together, these results constitute an important step toward the development of an integrated view of morphogenesis that incorporates mechanics.

us-immigration-statue-of-liberty-pixa

To the Editor:

We the undersigned, founders and leaders of biotech companies, write to express our deep concern and opposition to the executive order signed by President Donald Trump on January 27, 2017, barring the entry of citizens from seven countries into the United States1.

The United States is the world’s greatest developer of medicines and new inventions to ameliorate and cure intractable diseases, a status achieved through massive investment in private and public companies, academia and R&D. Most importantly, our success has been founded on the creativity and dedication of our most precious resource—our people.

medical-device-2-pixa

Tuesday, March 7th 8:00am—5:00pm

This one-day event will highlight the latest trends in medical devices and technologies and feature resources in the state that help bring products from invention to market. Topics include bioelectronics, cybersecurity for medical devices, convergence of devices and drugs, big data, robotic prosthetics, and additive manufacturing applications. Organizations representing Maryland innovation, entrepreneurial, funding, regulatory, and product scale-up resources will be there to discuss ways that they work with the medical device community.

This event is sponsored by the University of Maryland Robert E. Fischell Institute for Biomedical Devices, Maryland Manufacturing Extension Partnership, the Maryland Department of Commerce, Federal Laboratory Consortium (FLC), FLC Mid-Atlantic Region, National Institute for Standards and Technology Manufacturing Extension Partnership , and TEDCO.

friends-social-talk-pixa

Cuddles, kisses, and caring conversations. These are key ingredients of our close relationships. Scientists are finding that our links to others can have powerful effects on our health. Whether with romantic partners, family, friends, neighbors, or others, social connections can influence our biology and well-being.

NewImage

You thought the Shark Tank was tough? The second annual BioHealth Capital Region Crab Trap is now accepting applications!

Submit your application for a chance to be named the company with the most commercial potential at the BioHealth Capital Region Forum.

Deadline for entries is March 24 - Finalists will be announced by April 6 - Regional Biotech Forum Event: Panel Presentation is on April 20

under-armour-logo

The black sports bra and matching leggings that Under Armour began selling Monday don’t look particularly distinctive from the rest of the workout attire on its website.

But, in fact, the garments are different in a key way: They were made in the United States, marking a key milestone in the company’s ambitious bid to significantly rethink its manufacturing strategy.

mont-county-hans-riemer-logo

Build the MoCo STEM community by attending this free event for educators from pre-K to college, business leaders and employers, County Councilmembers, county government leaders and service providers, industry practitioners, interested parents and students. We are showcasing best practices, laying out a vision and asking for input on an effective STEM engagement strategy for Montgomery County.

12:30pm - 1pm: Networking and STEM Demonstrations

1pm - 4pm: Panels and Discussion

MCPS Superintendent Jack Smith to speak at 1:15pm

flc-award-winners-2017-logo

The Federal Laboratory Consortium for Technology Transfer congratulates the winners of its 2017 Awards. With over 90 nominations submitted this year’s competition was fierce, which made our judges’ task of selecting winners an unenviable one. We thank our winners, and their competitors, for a great job in realizing the technology transfer potential within their laboratories. 

The awards will be presented on Wednesday, April 26, 2017 at the FLC National Meeting in San Antonio, Texas. To register for the meeting and/or awards ceremony, visit meeting.federallabs.org.

nih-tech-transfer-logo

Chronic graft-versus-host disease (cGVHD) is a prevalent and highly lethal condition affecting stem cell transplant recipients. Unfortunately, biopsies are a painful, invasive and slow procedure that cause discomfort to patients and does not yield rapid results. The National Cancer Institute seeks licensees to commercialize this improved method for detection of diseases that are characterized by the presence of rapidly-dividing cells using deuterated water as a label for dynamic measurement of in vivo cellular kinetics.